ワークショップ3 ドライバー遺伝子陽性肺がんに対する治療戦略

[WS3-1] Lorlatinib vs crizotinib in patients with advanced ALK+NSCLC：5-year results from the CROWN study

^○Yasushi Goto¹, Benjamin J. Solomon², Geoffrey Liu³, Enriqueta Felip⁴, Tony S. K. Mok⁵, Ross A. Soo⁶, Julien Mazieres⁷, Alice T. Shaw⁸, Filippo de Marinis⁹, Yi-Long Wu¹⁰, Dong-Wan Kim¹¹, Jean-Francois Martini¹², Rossella Messina¹³, Jolanda Paolini¹³, Anna Polli¹³, Despina Thomaidou¹⁴, Francesca Toffalorio¹³, Todd M. Bauer¹⁵ (1.National Cancer Center Hospital, Tokyo, Japan, 2.Peter MacCallum Cancer Centre, Melbourne, VIC, Australia, 3.Princess Margaret Cancer Centre, Toronto, ON, Canada, 4.Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain, 5.State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, 6.National University Cancer Institute, Singapore, 7.Toulouse University Hospital and Centre de Recherche Cancérologie Toulouse CRCT, INSERM, France, 8.Massachusetts General Hospital Cancer Center, Boston, MA, USA, 9.European Institute of Oncology, IRCCS, Milan, Italy, 10.Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangdong, China, 11.Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea, 12.Pfizer, La Jolla, CA, USA, 13.Pfizer, Milan, Italy, 14.Pfizer, Athens, Greece, 15.Greco-Hainsworth Centers for Research/Tennessee Oncology, Nashville, TN, USA)

アンコール演題